

## References

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25 Suppl):D34-41.
2. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, and Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. *Cell Metab*. 2009;10(4):273-84. PMID: PMC2759401.
3. White K, Lu Y, Annis S, Hale AE, Chau BN, Dahlman JE, Hemann C, Opotowsky AR, Vargas SO, Rosas I, et al. Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. *EMBO Mol Med*. 2015;7(6):695-713. PMID: PMC4459813.
4. Anzovino A, Lane DJ, Huang ML, and Richardson DR. Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia. *Br J Pharmacol*. 2014;171(8):2174-90. PMID: PMC397662.
5. Ong KC, Geske JB, Hebl VB, Nishimura RA, Schaff HV, Ackerman MJ, Klarich KW, Siontis KC, Coutinho T, Dearani JA, et al. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. *European Heart Journal – Cardiovascular Imaging*. 2016;17(6):604-10.
6. Friedman RC, Farh KK, Burge CB, and Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res*. 2009;19(1):92-105. PMID: PMC2612969.
7. Bertero T, Lu Y, Annis S, Hale A, Bhat B, Saggari R, Saggari R, Wallace WD, Ross DJ, Vargas SO, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. *J Clin Invest*. 2014;124(8):3514-28. PMID: PMC4109523.
8. Bertero T, Cottrill KA, Annis S, Bhat B, Gochuico BR, Osorio JC, Rosas I, Haley KJ, Corey KE, Chung RT, et al. A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions. *Sci Rep*. 2015;5(18277). PMID: PMC4678880.
9. Bertero T, Cottrill KA, Lu Y, Haeger CM, Dieffenbach P, Annis S, Hale A, Bhat B, Kaimal V, Zhang YY, et al. Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit. *Cell Rep*. 2015;13(5):1016-32. PMID: PMC4644508.
10. Some phenotype data for this paper were retrieved from the Mouse Genome Database (MGD), Mouse Genome Informatics, The Jackson Laboratory, Bar Harbor, Maine. World Wide Web (URL:<http://www.informatics.jax.org>). (December 2016). Davisson MT, Cook SA, Eicher EM. The first spontaneous mutation in the mouse *Herc2* gene, MGI Direct Data Submission to Mouse Genome Database (MGD), MGI:1349786,(URL: <http://www.informatics.jax.org>). (1999).
11. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, and Koenig M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. *Nat Genet*. 2001;27(2):181-6.
12. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. *A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association*. 2009;119(16):2250-94.
13. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2009;54:S43-54.
14. Maron BA, and Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: A review. *JAMA Cardiology*. 2016.

15. Lai Y-C, Potoka KC, Champion HC, Mora AL, and Gladwin MT. Pulmonary Arterial Hypertension. The Clinical Syndrome. *Circ Res.* 2014;115(1):115-30. PMID: PMC4096686.
16. Archer SL, Weir EK, and Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. *Circulation.* 2010;121(18):2045-66. PMID: PMC2869481.
17. Rouault TA. Mammalian iron-sulphur proteins: novel insights into biogenesis and function. *Nat Rev Mol Cell Biol.* 2015;16(1):45-55.
18. Lill R. Function and biogenesis of iron–sulphur proteins. *Nature.* 2009;460(7257):831-8.
19. Martelli A, Schmucker S, Reutenauer L, Mathieu Jacques RR, Peyssonnaud C, Karim Z, Puy H, Galy B, Hentze Matthias W, and Puccio H. Iron Regulatory Protein 1 Sustains Mitochondrial Iron Loading and Function in Frataxin Deficiency. *Cell Metabolism.* 2015;21(2):311-22.
20. Kvistholm Jensen M, and Bundgaard H. Cardiomyopathy in Friedreich Ataxia. Exemplifying the Challenges Faced by Cardiologists in the Management of Rare Diseases. 2012;125(13):1591-3.
21. Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, Ravina B, Koeppen AH, and Lynch DR. Mortality in Friedreich Ataxia. *Journal of the Neurological Sciences.* 2011;307(1–2):46-9.
22. Thierbach R, Schulz TJ, Isken F, Voigt A, Mietzner B, Drewes G, von Kleist-Retzow J-C, Wiesner RJ, Magnuson MA, Puccio H, et al. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. *Human Molecular Genetics.* 2005;14(24):3857-64.
23. Schoenfeld RA, Napoli E, Wong A, Zhan S, Reutenauer L, Morin D, Buckpitt AR, Taroni F, Lonnerdal B, Ristow M, et al. Frataxin deficiency alters heme pathway transcripts and decreases mitochondrial heme metabolites in mammalian cells. *Human Molecular Genetics.* 2005;14(24):3787-99.
24. Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, Rai M, Acquaviva F, Coccozza S, Pandolfo M, and Geschwind DH. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPAR $\gamma$  pathway as a therapeutic target in Friedreich's ataxia. *Human Molecular Genetics.* 2009;18(13):2452-61. PMID: PMC2694693.
25. Martelli A, Friedman LS, Reutenauer L, Messaddeq N, Perlman SL, Lynch DR, Fedosov K, Schulz JB, Pandolfo M, and Puccio H. Clinical data and characterization of the liver conditional mouse model exclude neoplasia as a non-neurological manifestation associated with Friedreich's ataxia. *Disease Models & Mechanisms.* 2012;5(6):860-9. PMID: PMC3484868.
26. Chan SY and Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. *J Mol Cell Cardiol.* 2008;44:14-30. PMID: 17950310; PMID: PMC2234575.
27. Dahlman JE, Barnes C, Khan OF, Thiriou A, Jhunjunwala S, Shaw TE, Xing Y, Sager HB, Sahay G, Speciner L, et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. *Nat Nano.* 2014;9(8):648-55. PMID: PMC4207430.
28. Bertero T, Cottrill K, Krauszman A, Lu Y, Annis S, Hale A, Bhat B, Waxman AB, Chau BN, Kuebler WM and Chan SY. The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension. *J Biol Chem.* 2014;290:2069-2085. PMID: 25505270; PMID: PMC4303661.
29. Stenmark KR, Fagan KA, and Frid MG. Hypoxia-Induced Pulmonary Vascular Remodeling. *Cellular and Molecular Mechanisms.* 2006;99(7):675-91.
30. Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, White K, Mair KM, McClure JD, Southwood M, et al. A Role for miR-145 in Pulmonary Arterial Hypertension. Evidence From Mouse Models and Patient Samples. 2012;111(3):290-300.

31. Groth A, Vrugt B, Brock M, Speich R, Ulrich S, and Huber LC. Inflammatory cytokines in pulmonary hypertension. *Respiratory Research*. 2014;15(1):47. PMID: PMC4002553.
32. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA and Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. *Circ Res*. 2009;104:236-44, 28p following 244. PMID: 19074475.
33. Eruslanov E, and Kusmartsev S. In: Armstrong D ed. *Advanced Protocols in Oxidative Stress II*. Totowa, NJ: Humana Press; 2010:57-72.
34. Chang HC, Wu R, Shang M, Sato T, Chen C, Shapiro JS, Liu T, Thakur A, Sawicki KT, Prasad SV, et al. Reduction in mitochondrial iron alleviates cardiac damage during injury. *EMBO Molecular Medicine*. 2016.
35. Budhiraja R, Tuder RM, and Hassoun PM. Endothelial Dysfunction in Pulmonary Hypertension. *Circulation*. 2004;109(2):159-65.
36. Sakao S, Tatsumi K, and Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. *Respiratory Research*. 2009;10(1):95. PMID: PMC2768704.
37. Dromparis P, and Michelakis ED. Mitochondria in Vascular Health and Disease. *Annual Review of Physiology*. 2013;75(1):95-126.
38. Masri FA, Xu W, Comhair SAA, Asosingh K, Koo M, Vasanthi A, Drazba J, Anand-Apte B, and Erzurum SC. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*. 2007;293(3):L548-L554.
39. Young Lee M, Cagavi Bozkulak E, Schliffke S, Amos PJ, Ren Y, Ge X, Ehrlich BE, and Qyang Y. High density cultures of embryoid bodies enhanced cardiac differentiation of murine embryonic stem cells. *Biochemical and biophysical research communications*. 2011;416(1-2):51-7. PMID: PMC3237870.
40. Stellos K, Gatsiou A, Stamatelopoulos K, Perisic Matic L, John D, Lunella FF, Jae N, Rossbach O, Amrhein C, Sigala F, et al. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. *Nat Med*. 2016;22(10):1140- 50. PMC Journal in Process.
41. Xu W, and Erzurum SC. *Comprehensive Physiology*. John Wiley & Sons, Inc.; 2010.
42. Ciuculan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, et al. A Novel Murine Model of Severe Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*. 2011;184(10):1171-82.
43. Bauer M, Cheng S, Jain M, Ngoy S, Theodoropoulos C, Trujillo A, Lin F-C, and Liao R. Echocardiographic Speckle-Tracking Based Strain Imaging for Rapid Cardiovascular Phenotyping in Mice. *Circulation Research*. 2011;108(8):908-16. PMID: PMC3376717.
44. Song Y, Coleman L, Shi J, Beppu H, Sato K, Walsh K, Loscalzo J, and Zhang Y-Y. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. *American Journal of Physiology - Heart and Circulatory Physiology*. 2008;295(2):H677-H90. PMID: PMC2519229.
45. Das M, Fessel J, Tang H, and West J. A process-based review of mouse models of pulmonary hypertension. *Pulmonary Circulation*. 2012;2(4):415-33. PMID: PMC3555412.